Upscaling the production of AAV vectors is "not an easy task," Faust said. She chaired a session on tackling the global shortage of viral vectors on day one of the meeting.
"A lot of people are trying to improve the system," she said. "Another challenge is that the quality of AAV vectors that is going to be produced is going to be really variable."
Faust also highlighted the need for Europe to focus more on opportunities than risks to remain competitive in the market for advanced therapy medicinal products.
Click on the video below to learn more.